Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy</title><author><name sortKey="Maggiore, Ronald J" sort="Maggiore, Ronald J" uniqKey="Maggiore R" first="Ronald J." last="Maggiore">Ronald J. Maggiore</name><affiliation><nlm:aff id="A1">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Curran, Emily K" sort="Curran, Emily K" uniqKey="Curran E" first="Emily K." last="Curran">Emily K. Curran</name><affiliation><nlm:aff id="A1">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Witt, Mary Ellyn" sort="Witt, Mary Ellyn" uniqKey="Witt M" first="Mary Ellyn" last="Witt">Mary Ellyn Witt</name><affiliation><nlm:aff id="A2">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Haraf, Daniel J" sort="Haraf, Daniel J" uniqKey="Haraf D" first="Daniel J." last="Haraf">Daniel J. Haraf</name><affiliation><nlm:aff id="A2">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Vokes, Everett E" sort="Vokes, Everett E" uniqKey="Vokes E" first="Everett E." last="Vokes">Everett E. Vokes</name><affiliation><nlm:aff id="A1">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Cohen, Ezra E W" sort="Cohen, Ezra E W" uniqKey="Cohen E" first="Ezra E. W." last="Cohen">Ezra E. W. Cohen</name><affiliation><nlm:aff id="A1">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24472475</idno><idno type="pmc">4413907</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413907</idno><idno type="RBID">PMC:4413907</idno><idno type="doi">10.1016/j.jgo.2013.05.003</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">002656</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002656</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy</title><author><name sortKey="Maggiore, Ronald J" sort="Maggiore, Ronald J" uniqKey="Maggiore R" first="Ronald J." last="Maggiore">Ronald J. Maggiore</name><affiliation><nlm:aff id="A1">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Curran, Emily K" sort="Curran, Emily K" uniqKey="Curran E" first="Emily K." last="Curran">Emily K. Curran</name><affiliation><nlm:aff id="A1">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Witt, Mary Ellyn" sort="Witt, Mary Ellyn" uniqKey="Witt M" first="Mary Ellyn" last="Witt">Mary Ellyn Witt</name><affiliation><nlm:aff id="A2">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Haraf, Daniel J" sort="Haraf, Daniel J" uniqKey="Haraf D" first="Daniel J." last="Haraf">Daniel J. Haraf</name><affiliation><nlm:aff id="A2">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Vokes, Everett E" sort="Vokes, Everett E" uniqKey="Vokes E" first="Everett E." last="Vokes">Everett E. Vokes</name><affiliation><nlm:aff id="A1">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author><author><name sortKey="Cohen, Ezra E W" sort="Cohen, Ezra E W" uniqKey="Cohen E" first="Ezra E. W." last="Cohen">Ezra E. W. Cohen</name><affiliation><nlm:aff id="A1">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A3">University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of geriatric oncology</title><idno type="ISSN">1879-4068</idno><idno type="eISSN">1879-4076</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Objectives</title><p id="P1">Chemoradiation therapy (CRT) remains a potentially curative treatment in patients with locally advanced head/neck cancer (LA-HNC). However, survival and other outcomes in older patients with head/neck cancer receiving chemoradiotherapy are not well established. This study was performed to elucidate selected outcomes in this patient population.</p></sec><sec id="S2"><title>Materials and Methods</title><p id="P2">Retrospective study of LA-HNC patients ≥70 years of age who had received 5-fluorouracil-hydoxyurea-based CRT with a minimum of 3 years of follow up after therapy initiation was performed. Pre-treatment patient- and cancer-related characteristics were recorded. Survival data in addition to gastrostomy tube utilization, swallowing function, and hematologic toxicity were captured.</p></sec><sec id="S3"><title>Results</title><p id="P3">Eighty-nine patients treated between 1997 and 2009 were eligible for analysis (median age, 76 years; range, 70–94; male, 61%; ECOG PS, 0–1 43%; stage IVA/B, 71%). 86 were evaluable for survival analysis. 5-year overall and event-free survival were both at 32% with a median follow-up time of 39.2 months. The majority (86.5%) were able to complete all planned treatment cycles. A significant proportion of patients, however, required gastrostomy tube during CRT (62%) and developed aspiration during swallowing evaluation post-treatment (44%). Several patients required hospice (9%) or skilled nursing facility (13%) referrals during treatment.</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">Select older adults with LA-HNC can still experience long-term benefits despite 5-year survival rates lower than those historically reported in younger patients undergoing identical CRT regimens although potentially at higher risk for acute toxicities. Assessment and selection of those who can tolerate more intense combined-modality strategies and their long-term outcomes merit further larger, prospective studies.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">101534770</journal-id><journal-id journal-id-type="pubmed-jr-id">38530</journal-id><journal-id journal-id-type="nlm-ta">J Geriatr Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J Geriatr Oncol</journal-id><journal-title-group><journal-title>Journal of geriatric oncology</journal-title></journal-title-group><issn pub-type="ppub">1879-4068</issn><issn pub-type="epub">1879-4076</issn></journal-meta><article-meta><article-id pub-id-type="pmid">24472475</article-id><article-id pub-id-type="pmc">4413907</article-id><article-id pub-id-type="doi">10.1016/j.jgo.2013.05.003</article-id><article-id pub-id-type="manuscript">NIHMS614571</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Maggiore</surname><given-names>Ronald J.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A3">c</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Curran</surname><given-names>Emily K.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Witt</surname><given-names>Mary Ellyn</given-names></name><xref ref-type="aff" rid="A2">b</xref><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Haraf</surname><given-names>Daniel J.</given-names></name><xref ref-type="aff" rid="A2">b</xref><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Vokes</surname><given-names>Everett E.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Cohen</surname><given-names>Ezra E.W.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A3">c</xref></contrib></contrib-group><aff id="A1"><label>a</label>University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</aff><aff id="A2"><label>b</label>University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</aff><aff id="A3"><label>c</label>University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, IL, USA</aff><author-notes><corresp id="cor1"><label>*</label><italic>Corresponding author at:</italic> The University of Chicago Medical Center, 5841 S. Maryland Ave. MC 2115, Chicago, IL 60637, USA. Tel.: +1 773 702 4400; fax: +1 773 702 3163. <email>Ronald.maggiore@uchospitals.edu</email> (R.J. Maggiore)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>20</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>10</day><month>6</month><year>2013</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>4</month><year>2015</year></pub-date><volume>4</volume><issue>4</issue><fpage>327</fpage><lpage>333</lpage><pmc-comment>elocation-id from pubmed: 10.1016/j.jgo.2013.05.003</pmc-comment>
<permissions><copyright-statement>© 2013 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2013</copyright-year></permissions><abstract><sec id="S1"><title>Objectives</title><p id="P1">Chemoradiation therapy (CRT) remains a potentially curative treatment in patients with locally advanced head/neck cancer (LA-HNC). However, survival and other outcomes in older patients with head/neck cancer receiving chemoradiotherapy are not well established. This study was performed to elucidate selected outcomes in this patient population.</p></sec><sec id="S2"><title>Materials and Methods</title><p id="P2">Retrospective study of LA-HNC patients ≥70 years of age who had received 5-fluorouracil-hydoxyurea-based CRT with a minimum of 3 years of follow up after therapy initiation was performed. Pre-treatment patient- and cancer-related characteristics were recorded. Survival data in addition to gastrostomy tube utilization, swallowing function, and hematologic toxicity were captured.</p></sec><sec id="S3"><title>Results</title><p id="P3">Eighty-nine patients treated between 1997 and 2009 were eligible for analysis (median age, 76 years; range, 70–94; male, 61%; ECOG PS, 0–1 43%; stage IVA/B, 71%). 86 were evaluable for survival analysis. 5-year overall and event-free survival were both at 32% with a median follow-up time of 39.2 months. The majority (86.5%) were able to complete all planned treatment cycles. A significant proportion of patients, however, required gastrostomy tube during CRT (62%) and developed aspiration during swallowing evaluation post-treatment (44%). Several patients required hospice (9%) or skilled nursing facility (13%) referrals during treatment.</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">Select older adults with LA-HNC can still experience long-term benefits despite 5-year survival rates lower than those historically reported in younger patients undergoing identical CRT regimens although potentially at higher risk for acute toxicities. Assessment and selection of those who can tolerate more intense combined-modality strategies and their long-term outcomes merit further larger, prospective studies.</p></sec></abstract><kwd-group><kwd>Elderly</kwd><kwd>Geriatric</kwd><kwd>Head/neck cancer</kwd><kwd>Chemoradiation</kwd><kwd>Combined modality</kwd><kwd>Outcomes</kwd><kwd>Survival</kwd><kwd>Geriatric</kwd><kwd>Aspiration</kwd><kwd>Gastrostomy tube</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002656 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002656 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= EdenteV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.32. |  |